[Safety and immunogenicity of an anti-hepatitis-B vaccine obtained using the recombinant DNA technique: results of a longitudinal study in hospital personnel].
A prospective study of the immunogenicity, safety and persistence of antibodies induced by the DNA-recombinant anti-hepatitis B vaccine Engerix B was conducted in a risk group as health care workers. 115 health care workers were randomly allocated into two groups. Immunization was carried out according to a 0-1-6 month vaccination schedule in one group and to a 0-1-2-12 month schedule in the other group. Results indicate that the DNA-recombinant anti-hepatitis B vaccine is well tolerated and highly immunogenic. Reactogenicity to the vaccine was low in incidence and mild in severity with no significant difference appearing between the study groups.
Ricciardi
G
G
Ricercatore Università di Cassino.
Graziano
G
G
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D017325:Hepatitis B Vaccines / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007558:Italy; D008875:Middle Aged; D009784:Occupational Diseases / Q000517:prevention & control; D010564:Personnel, Hospital; D011446:Prospective Studies; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
C075654:Engerix-B; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Sicurezza ed immunogenicità di un vaccino anti-epatite B ottenuto con la tecnica del DNA-ricombinante: risultati di un'indagine longitudinale su personale ospedaliero.